CAS 936563-96-1 API Raw Material Ibrutinib For Antineoplastic Medicine Grade
Ibrutinib (Imbruvica) is a small molecule drug that binds permanently to a protein, Bruton's tyrosine kinase (BTK), that is important in B cells; the drug is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia, a form of non-Hodgkin's lymphoma.
White Crystalline Powder
1.Mantle cell lymphoma (MCL) who have received at least one prior therapy.
Ibrutinib is a highly selective Bruton’s tyrosine kinase (Btk) irreversible inhibitor.PCI-32765 (Ibrutinib) is a selective and irreversible pyrrolopyrimidine-based inhibitor of BTK with IC50 of 0.5 nM.  PCI-32765 binds irreversibly to Cys-481 in BTK and thus is only active with other kinases with such a modifiable cysteine residue. In DOHH2 cells, in which the BCR pathway can be activated by anti-IgG, PCI-32765 inhibits autophosphorylation of BTK (IC50, 11 nM), BTK's physiological substrate, PLCg (IC50, 29 nm), and downstream ERK (IC50, 13 nm).
Ibrutinib is used to treat chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, and as a second-line treatment for mantle cell lymphoma, marginal zone lymphoma, and chronic graft vs host disease.
White to whitish crystal powder
Loss on drying
Residue on ignition
Complies to the Enterprise standard.
Ibrutinib is a kind of Bruton tyrosine kinase (BTK) inhibitor, it could be used for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). MCL and CLL are belonged to the B-cell non-Hodgkin's lymphoma, which is difficult to cure and easy to recurrent. Common chemical immunotherapy does not have the targeting, often occurs 3 or 4 adverse reactions. Ibrutinib and B lymphocytes could target with BTK which is necessary for formation, differentiation, and transmission of information, inhibit BTK activity irreversibly, and inhibit tumor cell proliferation and survival effectively. Ibrutinib could be rapidly absorbed after oral administration, during 1~2h reach maximum blood concentration, adverse reactions belong to one or two, therefore, Ibrutinib will become a new choice of treatment of CLL and MCL.
Ibrutinib Is Used For:
Mantle cell lymphoma (MCL) who have received at least one prior therapy.
Chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.
How Ibrutinib Is Given:
Ibrutinib is a capsule, taken by mouth once daily. You may take 1-4 capsules at once depending on your prescribed dose.
Take ibrutinib at approximately the same time each day.
Take ibrutinib exactly as prescribed.
Swallow ibrutinib capsules whole with at least 8 ounces of water. Do not crush, open, chew or dissolve capsules.
Do not change your dose or stop ibrutinib unless your health care provider tells you to.
If you miss a dose of irbrutinib, it should be taken as soon as possible on the same day with return to the normal schedule the following day. Do not take extra capsules of ibrutinib to make up the next dose.
Do not take more than 1 dose of ibrutinib at one time. Call your health care provider and go to the emergency room right away if you take too much.
Store at room temperature (68째 F to 77째 F); keep medication in original bottle; protect from high humidity, moisture and light.
Keep out of reach from children and pets.
Safely throw away any ibrutinib that is out of date or unused (ask your provider for directions on how to discard the medication).
The amount of ibrutinib that you will receive depends on many factors, including your general health or other health problems, and the type of cancer or condition you have. Your doctor will determine your exact ibrutinib dosage and schedule.